SCHEMBL16979320

SCHEMBL16979320

CCN1CC[C@@H]1COC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16978993 1.00
SCHEMBL8391212 0.87 HDAC8 (0.44)
SCHEMBL4749550 0.87 HDAC8 (0.44)
SCHEMBL8391210 0.87 HDAC8 (0.44)
SCHEMBL12188160 0.85 HDAC8 (0.40)
SCHEMBL16939212 0.77 KDM4E (0.33)
SCHEMBL20715182 0.77 ALDH1A1 (0.36)
SCHEMBL22198680 0.77 L3MBTL1 (0.34)
SCHEMBL16939213 0.77 KDM4E (0.33)
SCHEMBL16941444 0.77 HDAC8 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023086383-A1 SELECT KRAS G12C INHIBITORS AND USES THEREOF 1200 PHARMA LLC (US) 2023-05-19 WO disclosed
WO-2022221704-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER HOTSPOT THERAPEUTICS, INC. (US) 2022-10-20 WO disclosed
WO-2015116786-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2015-08-06 WO disclosed